179 related articles for article (PubMed ID: 31949022)
1. Cardiomyopathy associated with the Ala143Thr variant of the
Valtola K; Nino-Quintero J; Hedman M; Lottonen-Raikaslehto L; Laitinen T; Maria M; Kantola I; Naukkarinen A; Laakso M; Kuusisto J
Heart; 2020 Apr; 106(8):609-615. PubMed ID: 31949022
[TBL] [Abstract][Full Text] [Related]
2. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.
Lenders M; Weidemann F; Kurschat C; Canaan-Kühl S; Duning T; Stypmann J; Schmitz B; Reiermann S; Krämer J; Blaschke D; Wanner C; Brand SM; Brand E
Orphanet J Rare Dis; 2016 May; 11(1):54. PubMed ID: 27142856
[TBL] [Abstract][Full Text] [Related]
3. Late-onset and classic phenotypes of Fabry disease in males with the
Valtola K; Hedman M; Kantola I; Walls S; Helisalmi S; Maria M; Raivo J; Auray-Blais C; Kuusisto J
Open Heart; 2023 Mar; 10(1):. PubMed ID: 36927868
[TBL] [Abstract][Full Text] [Related]
4. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Novel GLA Gene Mutation, p.Ile239Met, in Fabry Disease With a Predominant Cardiac Phenotype.
Csányi B; Hategan L; Nagy V; Obál I; Varga ET; Borbás J; Tringer A; Eichler S; Forster T; Rolfs A; Sepp R
Int Heart J; 2017 May; 58(3):454-458. PubMed ID: 28496025
[TBL] [Abstract][Full Text] [Related]
6. GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
Chaves-Markman ÂV; Markman M; Calado EB; Pires RF; Santos-Veloso MAO; Pereira CMF; Lordsleem ABMDS; Lima SG; Markman Filho B; Oliveira DC
Arq Bras Cardiol; 2019 Jul; 113(1):77-84. PubMed ID: 31291414
[TBL] [Abstract][Full Text] [Related]
7. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
8. Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.
Oikawa M; Sakamoto N; Kobayashi A; Suzuki S; Yoshihisa A; Yamaki T; Nakazato K; Suzuki H; Saitoh S; Kiko Y; Nakano H; Hayashi T; Kimura A; Takeishi Y
BMC Cardiovasc Disord; 2016 May; 16():83. PubMed ID: 27160240
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
[TBL] [Abstract][Full Text] [Related]
10. Clinical and genetic investigation of a Japanese family with cardiac fabry disease. Identification of a novel α-galactosidase A missense mutation (G195V).
Nakagawa N; Maruyama H; Ishihara T; Seino U; Kawabe J; Takahashi F; Kobayashi M; Yamauchi A; Sasaki Y; Sakamoto N; Ota H; Tanabe Y; Takeuchi T; Takenaka T; Kikuchi K; Hasebe N
Int Heart J; 2011; 52(5):308-11. PubMed ID: 22008442
[TBL] [Abstract][Full Text] [Related]
11. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease.
Oder D; Liu D; Hu K; Üçeyler N; Salinger T; Müntze J; Lorenz K; Kandolf R; Gröne HJ; Sommer C; Ertl G; Wanner C; Nordbeck P
Circ Cardiovasc Genet; 2017 Oct; 10(5):. PubMed ID: 29018006
[TBL] [Abstract][Full Text] [Related]
12. Nationwide screening for Fabry disease in unselected stroke patients.
Tomek A; Petra R; Paulasová Schwabová J; Olšerová A; Škorňa M; Nevšímalová M; Šimůnek L; Herzig R; Fafejtová Š; Mikulenka P; Táboříková A; Neumann J; Brzezny R; Sobolová H; Bartoník J; Václavík D; Vachová M; Bechyně K; Havlíková H; Prax T; Šaňák D; Černíková I; Ondečková I; Procházka P; Rajner J; Škoda M; Novák J; Škoda O; Bar M; Mikulík R; Dostálová G; Linhart A;
PLoS One; 2021; 16(12):e0260601. PubMed ID: 34905550
[TBL] [Abstract][Full Text] [Related]
13. Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y.
Oder D; Üçeyler N; Liu D; Hu K; Petritsch B; Sommer C; Ertl G; Wanner C; Nordbeck P
BMJ Open; 2016 Apr; 6(4):e010422. PubMed ID: 27059467
[TBL] [Abstract][Full Text] [Related]
14. Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography.
Spinelli L; Imbriaco M; Nappi C; Nicolai E; Giugliano G; Ponsiglione A; Diomiaiuti TC; Riccio E; Duro G; Pisani A; Trimarco B; Cuocolo A
Circ Cardiovasc Imaging; 2018 Apr; 11(4):e007019. PubMed ID: 29626078
[TBL] [Abstract][Full Text] [Related]
15. Sex Differences in Anderson-Fabry Cardiomyopathy: Clinical, Genetic, and Imaging Analysis in Women.
Faro DC; Losi V; Rodolico MS; Torrisi EM; Colomba P; Duro G; Monte IP
Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761944
[TBL] [Abstract][Full Text] [Related]
16. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants of unknown significance in alpha-galactosidase A: Cellular delineation from Fabry disease.
Klein A; Klug K; Breyer M; Grüner J; Medala VK; Nordbeck P; Wanner C; Klopocki E; Üçeyler N
J Inherit Metab Dis; 2024 Apr; ():. PubMed ID: 38618884
[TBL] [Abstract][Full Text] [Related]
18. [Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree].
Ge ZH; Lu ZH; Pan XD; Lai TT; Yang MJ; Yang HQ; Zhang HB; Li GY; Dai ZQ; Mao JH
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):345-350. PubMed ID: 38527505
[No Abstract] [Full Text] [Related]
19. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
[TBL] [Abstract][Full Text] [Related]
20. Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males.
Oliveira JP; Nowak A; Barbey F; Torres M; Nunes JP; Teixeira-E-Costa F; Carvalho F; Sampaio S; Tavares I; Pereira O; Soares AL; Carmona C; Cardoso MT; Jurca-Simina IE; Spada M; Ferreira S; Germain DP
Eur J Med Genet; 2020 Feb; 63(2):103703. PubMed ID: 31200018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
